Checkpoint Pharmaceuticals获得了生物技术巨头Regeneron的高溢价收购要约
截至美国东部时间周二下午1:41,临床阶段癌症专家CheckpointPharmaceuticals(CMPI329 46%)的股价上涨了328%。由于RegeneronPharmaceuticals
截至美国东部时间周二下午1:41,临床阶段癌症专家CheckpointPharmaceuticals(CMPI329 46%)的股价上涨了328%。由于RegeneronPharmaceuticals